SS-31

$269.00

Size

In stock
COA-verified
≥99% purity.
USA manufactured.
In stock
COA-verified
≥99% purity.
USA manufactured.
COA-verified
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.

What Is SS-31?

SS-31 (Elamipretide / MTP-131) is a synthetic, cell-permeable tetrapeptide engineered to selectively concentrate within the inner mitochondrial membrane. In research settings, SS-31 is studied for its interactions with cardiolipin — a phospholipid integral to mitochondrial cristae architecture and electron transport chain function.

BioRhex supplies SS-31 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.

SS-31 is a Szeto-Schiller peptide studied for its selective mitochondrial membrane targeting and cardiolipin interaction. In vitro and preclinical models examine how SS-31 may influence:

• Cardiolipin stabilization and mitochondrial cristae architecture in cellular models
• Electron transport chain efficiency and ATP synthesis dynamics
• Reactive oxygen species (ROS) generation within mitochondrial membrane systems
• Mitochondrial membrane potential regulation
• Apoptotic signaling pathways associated with mitochondrial dysfunction
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.

SS-31 was developed by Hazel Szeto and Peter Schiller during research into cell-permeable peptides with targeted mitochondrial accumulation. Its alternating aromatic-cationic structure was identified as the key feature enabling inner mitochondrial membrane concentration without associated cytotoxicity seen in earlier strategies.

Preclinical research demonstrated SS-31’s interactions with cardiolipin and its potential role in preserving mitochondrial structural integrity under oxidative stress conditions, establishing it as a research tool in mitochondrial biology.

SS-31 continues to be studied as a reference compound in mitochondria-targeted peptide research within controlled, non-clinical laboratory settings.

Reserch-grade coenzyme compound visualization.

COMPOUND

D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂

TYPE

Mitochondria-targeting peptide

MOLECULAR FORMULA

C₃₂H₄₉N₉O₅

MOLECULAR WEIGHT

639.8 g/mol

PURITY

≥99%

ANALYSIS

HPLC Verified

STORAGE

Store at -20°C. Protect from light and moisture.

CLASSIFICATION

Reserch Use Only

Research Findings

Published and preclinical research on SS-31 covers several areas of scientific investigation, including:

Cardiolipin interaction research: Studies examine SS-31’s binding dynamics with cardiolipin in inner mitochondrial membrane models.
Oxidative stress pathway modeling: Research explores SS-31’s interactions with ROS generation and mitochondrial oxidative signaling in preclinical systems.
Bioenergetics research: Laboratory findings evaluate ATP synthesis efficiency and electron transport chain function in SS-31 research models.
Apoptotic pathway modeling: Studies investigate mitochondrial permeability transition pore dynamics and cytochrome c release interactions.

All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.

References

1. Siegel MP, Kruse SE, Percival JM, et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763–771. https://doi.org/10.1111/acel.12102

2. Allen ME, Pennington ER, Perry JB, et al. (2021). The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae and biosynthetic constituents in mitochondria of fibroblasts from Barth syndrome patients. Cells, 10(11), 3125. https://doi.org/10.3390/cells10113125

3. Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029–2050. https://doi.org/10.1111/bph.12461

4. Chavez JD, Tang X, Campbell MD, et al. (2020). Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences, 117(26), 15363–15373. https://doi.org/10.1073/pnas.2002250117

FAQ

What type of research is SS-31 used for?

SS-31 is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.

Where is BioRhex’s SS-31 manufactured?

All BioRhex compounds, including SS-31, are manufactured in a GMP-compliant facility located in the United States.

What testing does BioRhex conduct on SS-31?

Every batch of SS-31 undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.

Is SS-31 approved for human use?

No. SS-31 is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.

Who should handle this compound?

Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.

All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. SS-31 is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.